Monotherapy with BRAFi and combined therapy with BRAFi and MEKi possess remarkable clinical activity in patients with metastatic BRAF-mutant melanoma - yielding objective response rates of 50–60% and of 65–75%, respectively - and significantly prolong progression-free and overall survival [39–41]. This evidence concerns the gene BRAF and melanoma.